-
2022-501576-25-00
5
2023-07-07
Melanoma
-
2024-512359-19-00
4
2023-05-12
Resectable Non-small cell lung cancer Pancoast tumor
-
2022-501139-17-01
4
2023-05-05
Aggressive Variant Metastatic Castration Resistant Prostate Cancer
-
2023-507187-39-00
5
2023-03-23
High-Risk Non-muscle-invasive Bladder Cancer
-
2023-505993-14-00
5
2023-01-05
Non-Small Cell Lung Cancer (NSCLC)
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-511412-25-00
4
2022-11-07
First line treatment for extensive-stage small cell lung cancer small
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2024-511268-10-00
4
2022-05-25
Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cel
-
2024-513866-20-00
4
2021-11-18
Non-small cell lung cancer with brain metastasis
-
2024-516039-28-00
6
2021-09-28
Spontaneous Coronary Artery Dissection.
-
2024-510809-28-00
5
2021-09-27
Metastatic Castration-sensitive Prostate Cancer
-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2024-513730-38-00
5
2021-01-13
Resectable Non-small cell lung cancer
-
2023-503421-19-00
5
2020-08-26
Urothelial cancer
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2023-509089-39-00
5
2020-07-01
Non-Muscle Invasive Bladder Cancer
-
2024-514604-14-00
4
2019-09-18
Muscle-invasive bladder cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2022-501817-29-00
5
2018-11-27
High Risk Non-muscle invasive bladder cancer
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer